Arab Finance: Minapharm Pharmaceuticals (Minapharm) (MIPH) has reported a 29.8% year-on-year (YoY) increase in standalone net profit after tax during the first quarter (Q1) of 2022, registering EGP 75.183 million, compared to EGP 57.92 million in Q1 2021, according to financial statements filed to the Egyptian Exchange (EGX) on May 30th.
Net sales soared to EGP 550.362 million in Q1 2022 from EGP 526.852 million in Q1 2021.
Minapharm Pharmaceuticals is an Egypt-based company engaged in the production and distribution of pharmaceutical products. It is in cooperation with several international pharmaceutical companies and it distributes its products within and outside Egypt.